# A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML

> **NCT05503355** · PHASE1,PHASE2 · UNKNOWN · sponsor: **BioSight Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- AML, Adult

## Interventions

- **DRUG:** BST-236
- **DRUG:** venetoclax

## Key facts

- **NCT ID:** NCT05503355
- **Lead sponsor:** BioSight Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-17
- **Primary completion:** 2025-08-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05503355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05503355, "A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05503355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*